These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8074473)

  • 1. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells.
    Nyoung MN; Trentesaux C; Aries A; Carpentier Y; Jardillier JC; Gorisse MC; Jeannesson P
    Anticancer Res; 1994; 14(3A):1203-8. PubMed ID: 8074473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells.
    Aries A; Trentesaux C; Ottolenghi S; Jardillier JC; Jeannesson P; Doubeikovski A
    Blood; 1996 Apr; 87(7):2885-90. PubMed ID: 8639908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of erythropoietin receptors during aclacinomycin-mediated erythroid differentiation of K562 leukemia cells.
    Jeannesson P; Trentesaux C; Nyoung MN; Mayeux P; Jacquot R; Jardillier JC
    Leukemia; 1991 Jan; 5(1):14-8. PubMed ID: 1847982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.
    Morceau F; Chénais B; Gillet R; Jardillier JC; Jeannesson P; Trentesaux C
    Cell Growth Differ; 1996 Aug; 7(8):1023-9. PubMed ID: 8853898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells.
    Trentesaux C; Nyoung MN; Aries A; Morceau F; Ronchi A; Ottolenghi S; Jardillier JC; Jeannesson P
    Leukemia; 1993 Mar; 7(3):452-7. PubMed ID: 8445949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Culture conditions modulate the effects of aclacinomycin A on growth, differentiation and apoptosis of HL60 cells.
    Mayer P; Carpentier Y; Gorisse MC; Desoize B
    Anticancer Res; 1994; 14(6A):2331-7. PubMed ID: 7825968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
    Millot JM; Rasoanaivo TD; Morjani H; Manfait M
    Br J Cancer; 1989 Nov; 60(5):678-84. PubMed ID: 2803945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells.
    Morceau F; Aries A; Lahlil R; Devy L; Jardillier JC; Jeannesson P; Trentesaux C
    Biochem Pharmacol; 1996 Mar; 51(6):839-45. PubMed ID: 8602880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative effects of hemin and anthracyclines in promoting terminal erythroid maturation in K562 human erythroleukemia cells.
    Tsiftsoglou AS; Wong W; Tsamadou AI; Robinson SH
    Exp Hematol; 1991 Oct; 19(9):928-33. PubMed ID: 1893971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
    Jakubowska J; Wasowska-Lukawska M; Czyz M
    Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives.
    Szulawska A; Arkusinska J; Czyz M
    Biochem Pharmacol; 2007 Jan; 73(2):175-84. PubMed ID: 17097070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells.
    Tang Y; McGoron AJ
    J Photochem Photobiol B; 2009 Dec; 97(3):138-44. PubMed ID: 19811928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
    Jakubowska J; Stasiak M; Szulawska A; Bednarek A; Czyz M
    Acta Biochim Pol; 2007; 54(4):839-46. PubMed ID: 17957275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracyclines as tumor cell differentiating agents: effects on the regulation of erythroid gene expression.
    Jeannesson P; Lahlil R; Chenais B; Devy L; Gillet R; Aries A; Morceau F; Trentesaux C
    Leuk Lymphoma; 1997 Aug; 26(5-6):575-87. PubMed ID: 9389364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of doxorubicin-induced apoptosis and differentiation by indomethacin in K-562 leukemia cells.
    Cipák L; Paulíková H; Novotný L; Jarosová M; Rauko P
    Neoplasma; 2004; 51(3):188-92. PubMed ID: 15254671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple combination of retinoic acid+aclacinomycin A+ dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture.
    Hassan HT; Rees JK
    Anticancer Res; 1989; 9(3):647-51. PubMed ID: 2764511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative morphological assessment of erythroblastic differentiation induced, in vitro, in human K562 leukemic cells.
    Broglio C; Dufer J; Joly P; Carpentier Y; Desplaces A
    Anal Cell Pathol; 1993 May; 5(3):135-46. PubMed ID: 8343432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
    Shin DH; Choi KS; Park SA; Cho BS; Lee HS; Ryu JS; Kim TY; Lee CK; Song S; Chung YB
    Arch Pharm Res; 2008 Oct; 31(10):1355-61. PubMed ID: 18958428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.